Cormorant Asset Management LP 13D and 13G filings for Kala Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 3:01 pm Purchase | 2024-12-31 | 13G | Kala Pharmaceuticals, Inc. KALA | Cormorant Asset Management LP | 609,027 9.990% | 609,027 (New Position) | Filing |